C84.64 Anaplastic large cell lymphoma, ALK-positive, lymph nodes of axilla and upper limb

Name of the Condition

• Anaplastic large cell lymphoma, ALK-positive, lymph nodes of axilla and upper limb (ICD-10 Code: C84.64)

Summary

Anaplastic large cell lymphoma, ALK-positive, lymph nodes of axilla and upper limb (ALCL, ALK-positive) is a rare subtype of non-Hodgkin lymphoma that primarily affects T-lymphocytes. It is characterized by the presence of the anaplastic lymphoma kinase (ALK) protein, resulting from a specific genetic rearrangement. This condition typically presents as a rapidly growing tumor involving the lymph nodes of the axilla and upper limb. ALCL, ALK-positive is more common in children and young adults and is generally considered aggressive but responsive to targeted therapies.

Causes

The exact cause of ALK-positive ALCL is not fully understood. The disease is driven by a genetic translocation involving the ALK gene, most commonly the t(2;5)(p23;q35) translocation, which results in overexpression of the ALK protein. This abnormal protein promotes uncontrolled cell growth and survival. While the translocation is a key driver, other genetic mutations may contribute to disease development, though specific environmental triggers remain unclear.

Risk Factors

• Age: More common in children and young adults, with a peak incidence in the second and third decades of life.
• Gender: Slightly higher prevalence in males.
• Genetic factors: Presence of the ALK translocation is a primary risk factor.
• Immunosuppression: Weakened immune systems may increase susceptibility.

Symptoms

• Rapidly enlarging, painless lymph node swelling in the axilla or upper limb.
• Systemic symptoms such as fever, night sweats, or unexplained weight loss (B symptoms) may occur.
• Skin lesions or other soft tissue involvement in some cases.
• Fatigue or general malaise.

Diagnosis

Diagnosis involves a combination of clinical evaluation, imaging studies (e.g., CT or PET scans), and biopsy of the affected lymph node. Histopathological examination reveals characteristic large, anaplastic cells with CD30 positivity and ALK protein expression. Molecular testing confirms the ALK translocation. Staging helps determine the extent of disease.

Treatment Options

Treatment typically includes systemic chemotherapy, often with regimens like CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Targeted therapies, such as ALK inhibitors (e.g., crizotinib), may be used for ALK-positive cases. Radiation therapy may be employed for localized disease. Stem cell transplantation is considered for relapsed or refractory cases.

Prognosis and Follow-Up

Prognosis varies based on disease stage, response to treatment, and patient factors. ALK-positive ALCL generally has a better prognosis than ALK-negative subtypes, with higher response rates to therapy. Regular follow-up with imaging and clinical assessments is essential to monitor for recurrence or progression.

Complications

• Disease progression or relapse despite treatment.
• Treatment-related side effects, such as infection risk from chemotherapy.
• Long-term complications from radiation or targeted therapies.
• Potential spread to other organs or tissues.

Lifestyle & Prevention

• Maintain a healthy immune system through balanced nutrition and regular exercise.
• Avoid known immunosuppressive factors, such as smoking or excessive alcohol use.
• Follow recommended cancer screening guidelines for early detection of related conditions.
• Manage stress and prioritize adequate rest to support overall health.

When to Seek Professional Help

Seek immediate medical attention if you experience persistent, unexplained lymph node swelling in the axilla or upper limb, especially if accompanied by fever, night sweats, or weight loss. Early evaluation is critical for timely diagnosis and treatment.

Tips for Medical Coders

When coding for C84.64, ensure documentation specifies the involvement of lymph nodes in the axilla and upper limb. Verify that the diagnosis aligns with ALK-positive status, as this distinguishes it from other lymphoma subtypes. Confirm the absence of more specific site codes (e.g., for skin or other tissues) to avoid miscoding. Accurate clinical documentation is essential for proper code assignment.